Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
Int J Nanomedicine · 2017
Last updated 2026-05-28Researchers created a new delivery system for the GLP-1 drug exenatide using a polymer called PEG--(PELG--PLL). In lab tests, 20.16% to 76.88% of the drug was released over 7 days. In diabetic rats, the new system kept blood sugar controlled for 7 days and improved kidney function compared to free exenatide.
AI summary of the abstract below.
| Journal | Int J Nanomedicine, 2017 |
|---|---|
| Citations | 23 |
| Relative citation ratio | 1.10 |
| NIH percentile | 54 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
The poly(ethylene glycol)--brush poly(l-lysine) polymer (PEG--(PELG--PLL)) was synthesized and evaluated as a nanocarrier for prolonging delivery of exenatide through the abdominal subcutaneous injection route. The isoelectric point of exenatide was 4.86, and exenatide could combine with PEG--(PELG--PLL) polymers via electrostatic interactions at pH 7.4. This polymer was a good candidate for achieving prolonged drug delivery for exenatide, considering its high molecular weight. Besides the physicochemical characterization of the polymer, in vitro and in vivo applications were researched as a sustained exenatide delivery system. In the in vitro release research, 20.16%-76.88% of total exenatide was released from the PEG--(PELG--PLL) polymer within 7 days. The synthesized block-brush polymers and exenatide-block-brush polymers were analyzed by nuclear magnetic resonance spectroscopy, gel permeation chromatography, transmission electron microscopy, nanoparticle size instrument, and scanning electron microscopy. The best formulation was selected for in vivo experimentation to achieve blood glucose control in diabetic rat models using free exenatide as the control. The hypoglycemic action of the formulation following subcutaneous injection in diabetic rats lasted 7 days, and the results indicated that exenatide-block-brush polymers demonstrate enhanced long-acting hypoglycemic action. Besides the hypoglycemic action, exenatide-block-brush polymers significantly alleviated diabetic nephropathy via improving renal function, decreasing oxidative stress injury, decreasing urinary albumin excretion rate, mitigating albumin/creatinine ratio, reducing blood lipids, abating kidney index, weakening apoptosis, and downregulating expression of connective tissue growth factor. All of the results suggested that PEG--(PELG--PLL) polymers could be used as potential exenatide nanocarriers, with efficient encapsulation and sustained release.
Verbatim abstract via PubMed 28721043 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.